Trial Profile
Randomized, open-label, 4-way reference replicated crossover bioequivalence study of donafenib 100 mg tablet (producted by Zelgen versus WuXi AppTec) in healthy subjects under fasting conditions
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2018
Price :
$35
*
At a glance
- Drugs Donafenib (Primary)
- Indications Colorectal cancer; Gastric cancer; Liver cancer; Nasopharyngeal cancer; Oesophageal cancer; Thyroid cancer
- Focus Pharmacokinetics
- 17 Jul 2018 New trial record